IMCR Immunocore Holdings plc Net earnings per share growth this year

IMCR (Immunocore Holdings plc) - company brandmark

The annual EPS volatility reflects the profit dynamics of Immunocore Holdings plc (IMCR). The 67.90 level serves as a critical benchmark for analysis. Immunocore Holdings plc (IMCR) holds a unique melanoma drug, establishing a monopoly position. Development relies on a patent-protected TCR platform, which creates high barriers to entry for new players. However, current business scaling depends directly on future FDA approvals for the therapy of new tumor types.

Immunocore (IMCR): Net earnings per share growth this year from 07/04/2022 to 11/18/2026

Analytical breakdowns and data insights for company Immunocore Corp (IMCR)

- current quotes and average value forecast:
Summary company analysis:IMCR (Immunocore Holdings plc)
Brand item of Immunocore PLC

For Immunocore Holdings plc (IMCR), whose revenue depends on the commercial success of KIMMTRAK, this metric reflects the effectiveness of immunotherapy monetization through earnings per share dynamics. By analyzing the history of annual net income growth per share, an investor assesses the percentage change in EPS relative to the previous year, which allows them to filter out market noise and determine the phase of the business's fundamental growth.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year januxrx.com|Net earnings per share growth this year arcusbio.com (RCUS)|Earnings per share growth in current year Zymeworks Inc (ZYME)|Net earnings per share growth this year Tango Pharma TNGX|Iovance Biotherapeutics Inc - Net earnings per share growth this year|Earnings growth in current year Immatics Biotechnologies IMTX|XNCR - Earnings per share growth in current year|CMPX (compasstherapeutics.com) - Earnings per share growth this year|Replimune Inc. (REPL) - Earnings per share growth in current year|Earnings per share growth rate in current year Lyell Immunopharma Inc (LYEL)|Net earnings per share growth this year IPHA|PYXS - Net earnings per share change in current year|Net earnings per share growth this year CGEN (Compugen Ltd.)|Net earnings per one share growth for the current year IOBT|Earnings growth in current year STRO (Sutro Biopharma)|Earnings per share increase in current year INKT|Werewolf - Earnings growth in current year|Earnings per share growth rate in current year Immix Biopharma|ALX Oncology (ALXO) - Earnings per share growth in current year|cuebiopharma.com (CUE) - Earnings growth in current year|PDSB (PDS Biotechnology Corp) - Earnings growth in current year|Earnings growth in current year sonnetbio.com|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|nextcure.com (NXTC) - Earnings per share growth rate in current year|LPTX - Earnings per share growth in current year|Expected net earnings per share growth this year Intensity Therapeutics, Inc. INTS|SNSE: Earnings growth in current year|Synthetic Biologics - Earnings per share increase in current year|GRTS (Gritstone bio) - Earnings growth in current year|KA (Kineta, Inc.) - Net earnings per one share growth for the current year|Earnings growth in current year NEXI|Turnstone Biologics Corp - Earnings per share growth this year|Earnings growth in current year VCNX (Vaccinex Inc)|Harpoon Therapeutics Corp (HARP) - Earnings per share growth rate in current year